Providers should transition to emerging weight loss peptides when a patient experiences intractable side effects (like severe nausea or gastroparesis), when they hit a hard weight loss plateau despite dietary compliance, or when the primary clinical obstacle is documented cellular metabolic resistance rather than hyperphagia (overeating)
Moreover, Kim et al
The semaglutide group also experienced fewer fractures than the control group
amino acids oxidases, cyclooxygenase, lipoxygenase, nitric oxide synthase, xanthine oxidase, NADPH oxidase), oxidative protein folding in the endoplasmic reticulum (ER), the oxidation of free fatty acids (FFAs) in peroxisomes and microsomes, through the effect of pro-inflammatory cytokines, and in the mitochondrial respiratory chain
Strictly not for human or veterinary use outside approved clinical trials
Biochem Pharmacol 2003;65:1483-8